Human Papillomavirus (HPV) DNA Detection Using Self-Sampling Devices in Women Undergoing Long Term Immunosuppressive Therapy

Wielgoś, Aleksandra; Pietrzak, Bronisława; Sikora, Mariusz; Martirosian, Gayane; Suchońska, Barbara; Gozdowska, Jolanta; Ołdakowska‐Jedynak, Urszula; Jabiry-Zieniewicz, Zoulikha; Durlik, Magdalena; Rudnicka, Lidia; Wielgoś, Mirosław

doi:10.3390/v12090962

Cited by 9 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hrHPV prevalence in RTRs varies in different areas. Although some studies reported no difference in hrHPV infection rates between kidney transplant recipients and their matched controls ( 11 – 13 ), most studies confirmed a significantly higher prevalence of cervical hrHPV among RTRs ( 14 – 17 ). The 2019 American Society of Colposcopy and Cervical Pathology (ASCCP) consensus guidelines emphasized the importance of regular cervical cancer screening for patients with immunosuppression ( 18 ).…”

Section: Introductionmentioning

confidence: 94%

Risk of human papillomavirus infection and cervical intraepithelial lesions in Chinese renal transplant recipients

et al. 2022

View full text Add to dashboard Cite

ObjectiveWhile human papillomavirus (HPV) infection in women is associated with cervical intraepithelial neoplasia and cervical cancer, HPV testing is not often performed in routine practice for renal transplantation patients. The genotype-specific prevalence of HPV and risk factors for HPV infection are still unclear.MethodsFrom 2010 to 2020, patients receiving renal transplantation surgery (referred to as RTRs), who had been screened for HPV infection one year after transplantation were enrolled. A comparison cohort of four age- and marital status-matched healthy individuals was selected for RTRs. The clinical characteristics and cervical screening results of RTRs were analyzed.ResultsOur study included 196 female renal transplant recipients (RTRs), none of whom had been vaccinated against HPV. Overall high-risk HPV (hrHPV) infection and abnormal cytology rates in the RTR group were 23.5% and 20.9%, respectively. The odds ratios of hrHPV infection and cervical intraepithelial neoplasia grade 2+ in RTRs vs. non-RTRs were 3.033 (95% CI, 2.013-4.568) and 3.628 (95% CI, 1.863-7.067), respectively. The prevalence of HPV16 in RTRs was much higher (30.4% vs. 8.3%, P=0.002). The multi-infection rate was much higher in HPV-infected RTRs (23.9% vs. 1.14%, P<0.001). The only risk factor for hrHPV infection was the duration of immunosuppression, which increased with time.ConclusionRTRs had significantly higher HPV infection rates and increased risks of HPV-related cervical premalignancies and cancers due to the immunosuppressed state. The duration of immunosuppression is a risk factor for transplant recipients. Female RTRs may benefit from more frequent cervical cancer screening after renal transplantation than healthy women. Prospective research on HPV infection dynamics in RTRs and optimal screening methods should be further explored in the future.

show abstract

Section: Introductionmentioning

confidence: 94%

Risk of human papillomavirus infection and cervical intraepithelial lesions in Chinese renal transplant recipients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…HPV 45 was the most common genotype (3.3%) and only one patient tested positive for HPV 16 (1.7%) [20]. Nevertheless, in other European studies, including renal-transplant women and patients undergoing immunosuppressive therapies for at least 3 months, HPV 16 was dominant [19,23].…”

Section: Discussionmentioning

confidence: 89%

Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region

Boudes

Venard

Routiot³

et al. 2021

Viruses

View full text Add to dashboard Cite

Background: The primary objective of this work was to assess the prevalence and distribution of HPV genotypes in immunosuppressed patients, and to compare them with the French Monsonego cohort. Secondary objectives were to evaluate whether the risk of HPV infection was correlated with HIV viral load, CD4 cell count in HIV-infected patients and the type, number of immunosuppressive therapies or type of pathology (transplant vs. autoimmune diseases) in patients undergoing long-term immunosuppressive therapy. Methods: An observational, monocentric and historical study was conducted including all immunosuppressed patients having received an HPV testing, in the Laboratory of Virology, Nancy Regional Teaching Hospital Center, between 2014 and 2020. Immunosuppressed patients were either HIV-infected or received long-term immunosuppressive therapy. Results: In our cohort, the prevalence of HPV infection (75.6% vs. 16.1% p < 0.05), the proportion of patients with high-risk HPV infection (48.9% vs. 15.1% p < 0.05) and with multiple HPV infection (41.1% vs. 5.7% p < 0.05) were significantly higher than in the Monsonego cohort. HPV 52 (13%), 53 (13%) and 16 (10%) were the most common in the immunosuppressed population, while it was HPV 16, 42 and 51 in the Monsonego cohort. Conclusions: This study supports that a particular attention must be given to all the immunosuppressed patients for the screening and care of HPV-related diseases because of major modifications of HPV epidemiology compared with the overall population.

show abstract

“…The exclusion criteria constituted of menstruation on the day of a possible enrollment or a history of cervical cancer. The patients invited to participate in the study were chosen randomly based on their presence in the Institute of Transplantology or the outpatient clinics during the enrollment period as there is no nationwide registry of immunocompromised patients in Poland [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

A Six-Year Gynecological Follow-Up of Immunosuppressed Women with a High-Risk Human Papillomavirus Infection

Wielgoś

Pietrzak

Suchońska

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Immunocompromised women are at an increased risk of developing malignancies, especially those that are viral-induced, such as invasive cervical cancer caused by the human papillomavirus (HPV). The aim of the study was to describe gynecological follow-up of women undergoing chronic immunosuppressive therapy for various reasons (e.g., kidney/liver transplant, systemic lupus erythematosus), diagnosed with a high-risk HPV (hrHPV) infection based on a self-sampling test. Twenty-six hrHPV-positive women were invited to take part in a gynecological follow-up, including a visual assessment of the anogenital region, two-handed gynecological examination, and cervical cytology as well as a colposcopy and cervical biopsy when necessary. Four women declined taking part in the study. Over six years of observation, low-grade squamous intraepithelial lesions (LSIL) were detected at least once in 7/22 women (31.8%), and a cervical intraepithelial lesion 1 (CIN 1) histopathologic result was obtained five times in 3/22 women. No cases of high-grade squamous intraepithelial lesions, CIN 2/3, or invasive cervical cancers were observed. Loop electrosurgical excision procedure (LEEP) was performed in three patients. As immunocompromised women are prone to persistent hrHPV infections, they should be under strict gynecological supervision because only vigilant surveillance enables fast detection and treatment of early dysplasia and, therefore, provides a chance for the reduction of the cervical cancer burden.

show abstract

Human Papillomavirus (HPV) DNA Detection Using Self-Sampling Devices in Women Undergoing Long Term Immunosuppressive Therapy

Cited by 9 publications

References 24 publications

Risk of human papillomavirus infection and cervical intraepithelial lesions in Chinese renal transplant recipients

Risk of human papillomavirus infection and cervical intraepithelial lesions in Chinese renal transplant recipients

Prevalence and Distribution of HPV Genotypes in Immunosuppressed Patients in Lorraine Region

A Six-Year Gynecological Follow-Up of Immunosuppressed Women with a High-Risk Human Papillomavirus Infection

Contact Info

Product

Resources

About